This live session took place on September 20, 2018
Rapid growth in the Chinese cardiovascular and orthopedic market and large foreseeable opportunities have attracted significant investment from both multinational competitors and local players alike over the past decade. However, rising health care expenditure has forced the Chinese government to implement cost-cutting initiatives, such as the Made in China 2025 program, introducing hospital guidelines to purchase more domestic products, and amendments to provincial reimbursement policies, which has significantly altered the competitive landscape in some cardiovascular and orthopedic device markets.
This webinar answered:
Please complete the form below view the webinar recording